| Resistant mechanisms to BRAF inhibitors in melanoma JL Manzano, L Layos, C Bugés, M de los Llanos Gil, L Vila, ... Annals of translational medicine 4 (12), 2016 | 276 | 2016 |
| The epidermal growth factor receptor (EGRF) in lung cancer E Carcereny, T Morán, L Capdevila, S Cros, L Vilà, M de los Llanos Gil, ... Translational respiratory medicine 3, 1-8, 2015 | 53 | 2015 |
| IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas O Etxaniz, C Carrato, I de Aguirre, C Queralt, A Muñoz, JL Ramirez, ... Journal of neuro-oncology 135, 273-284, 2017 | 26 | 2017 |
| Targeting EML4-ALK driven non-small cell lung cancer (NSCLC) T Morán, V Quiroga, M de los Llanos Gil, L Vilà, N Pardo, E Carcereny, ... Translational lung cancer research 2 (2), 128, 2013 | 25 | 2013 |
| A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results … E Felip, M Majem, B Doger, TD Clay, E Carcereny, I Bondarenko, ... Journal of Clinical Oncology 40 (16_suppl), 9003-9003, 2022 | 24 | 2022 |
| Outcome prognostic factors in inoperable malignant bowel obstruction M Romeo, M de los LLanos Gil, JL Cuadra Urteaga, L Vilà, S Ahlal, ... Supportive Care in Cancer 24, 4577-4586, 2016 | 18 | 2016 |
| Treatment in esophagogastric junction cancer: Past, present and future C Pericay, I Macías-Declara, V Arrazubi, L Vilà, M Marín Cirugía Española (English Edition) 97 (8), 459-464, 2019 | 11 | 2019 |
| Estado emocional en mujeres con cáncer de mama: variación experimentada después de una sesión psico-oncológica basada en el counselling y la psicología positiva. Psicooncología … L Vila, A Font, L Caba PSIC 54433, 2016 | 9 | 2016 |
| A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant … V Calvo, M Domine, I Sullivan, JL Gonzalez-Larriba, AL Ortega, ... Journal of Clinical Oncology 39 (15_suppl), TPS8581-TPS8581, 2021 | 7 | 2021 |
| “High tumor burden” in metastatic non-small cell lung cancer: defining the concept OH Gómez, AM Paul, ALO Granados, SR Martínez, DP Parente, ... Cancer Management and Research 13, 4665, 2021 | 6 | 2021 |
| A single-center retrospective study of patients with double primary cancers: breast cancer and EGFR-mutant non-small cell lung cancer T Moran, V Quiroga, B Cirauqui, L Vila, M Gil-Moreno, E Carcereny, ... Oncology Research and Treatment 42 (3), 107-114, 2019 | 6 | 2019 |
| “High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept O Higuera Gómez, A Moreno Paul, AL Ortega Granados, S Ros Martínez, ... Cancer Management and Research, 4665-4670, 2021 | 5 | 2021 |
| Teleoncology: A solution for everyone? A single-center experience with telemedicine during the coronavirus disease 2019 (COVID-19) pandemic P Ribera, S Soriano, C Climent, L Vilà, I Macias, LA Fernández-Morales, ... Current Oncology 29 (11), 8565-8578, 2022 | 4 | 2022 |
| La atención odontológica del paciente con deficiencia auditiva. Artículos de reflexión A Encina, S Martínez, L Vila, C Barrios Acta Odontol Colomb 2 (2), 211-216, 2012 | 4 | 2012 |
| 1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic … BC Cho, CA de la Rosa, L Vilà, D Isla, J Oliveira, J de Castro Carpeno, ... Annals of Oncology 32, S1034-S1035, 2021 | 2 | 2021 |
| Tratamientos oncológicos en el cáncer de unión esofagogástrica: pasado, presente y futuro C Pericay, I Macías-Declara, V Arrazubi, L Vilà, M Marín Cirugía Española 97 (8), 459-464, 2019 | 2 | 2019 |
| 1641P Patient preferences towards the application of telemedicine on cancer care during Coronavirus disease 2019 (COVID-19) pandemic. ONCOTELEMED STUDY P Ribera, C Climent, S Soriano, IM Declara, L Fernandez, L Vilà, ... Annals of Oncology 32, S1159-S1160, 2021 | 1 | 2021 |
| Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer M Peressini, R Garcia-Campelo, B Massuti, C Marti, M Cobo, V Gutiérrez, ... Clinical Cancer Research, 2024 | | 2024 |
| The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy A Gómez Rueda, Á Taus, R Álvarez Álvarez, R Bernabé-Caro, L Chara, ... Clinical and Translational Oncology, 1-11, 2024 | | 2024 |
| P2. 14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study R García-Campelo, MD Gómez, J de Castro, AM Vega, SP Aix, E Arriola, ... Journal of Thoracic Oncology 18 (11), S372, 2023 | | 2023 |
